Worth watching Stocks: Arch Coal (NYSE:ACI), MannKind Corporation (NASDAQ:MNKD), AK Steel Holding (NYSE:AKS), Arena Pharmaceuticals (NASDAQ:ARNA)



Arch Coal Inc (NYSE:ACI) has been given a consensus rating of “Hold” by the eighteen brokerages that are presently covering the company, AnalystRatingsNetwork.com reports. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating on the company. Arch Coal Inc (NYSE:ACI) stock performance was -0.64% in last session and finished the day at $4.66. Traded volume was 11.69million shares in the last session and the average volume of the stock remained 8.84million shares. The beta of the stock remained 1.85. Arch Coal Inc (NYSE:ACI) insider ownership is 0.54%.

Shares of MannKind Corporation (NASDAQ:MNKD) were the recipient of some unusual options trading activity on Monday. Traders purchased 21,101 call options on the company, AnalystRatings.NET reports. This is an increase of approximately 105% compared to the average daily volume of 10,311 call options. MannKind Corporation (NASDAQ:MNKD) dropped -1.86 percent to $5.80 Tuesday on volume of 8.76million shares. The intra-day range of the stock was $5.75 to $6.01. MannKind Corporation (NASDAQ:MNKD) has a market capitalization of $2.19billion.

An old-line Cincinnati business cranked out some new-economy-type stock gains when AK Steel Holding Corporation (NYSE:AKS) shares surged last week. A brighter outlook about steel makers’ ability to raise prices and a strong earning report fueled AK Steel Holding Corporation (NYSE:AKS) to a 13 percent gain in a week. That lifted the stock to $6.97. AK Steel Holding Corporation (NYSE:AKS)’s stock on Mar 25, 2014 reported a increase of 1.74% to the closing price of $7.02. Its fifty two weeks range is $2.76 -$8.47. The total market capitalization recorded $959.52million. The overall volume in the last trading session was 8.02million shares. In its share capital, AKS has 135.90million outstanding shares.

San Diego’s Arena Pharmaceuticals Inc (NASDAQ:ARNA), in a race to dominate the market for anti-obesity drugs, is expected to unveil an advertising campaign next month directly targeting consumers. On Tuesday, shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) advanced 0.50% to close the day at $6.05. Company return on investment (ROI) is -13.90% and its monthly performance is recorded as -13.69%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly revenue growth is 8.62%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone